SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Sigvardsson Ola)
 

Search: WFRF:(Sigvardsson Ola) > Type 1 Diabetes Mel...

  • Davies, Lindsay C.Karolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden (author)

Type 1 Diabetes Mellitus Donor Mesenchymal. Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-07-13
  • Oxford University Press (OUP),2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-308913
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-308913URI
  • https://doi.org/10.5966/sctm.2015-0272DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:134521773URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-132846URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • De två första författarna delar förstaförfattarskapet.Den tredje och fjärde författaren delar på andra författarskapet.
  • Funding Agencies|Swedish Cancer Society; Childrens Cancer Foundation; Swedish Medical Research Council; VINNOVA; Stockholm County Council (ALF); Cancer Society in Stockholm; Swedish Society of Medicine; Tobias Foundation; Karolinska Institutet; Juvenile Diabetes Foundation International; AFA Insurance; Swedish Diabetes Association; Swedish Juvenile Diabetes Foundation; Novo Nordisk Foundation; Diabetes Wellness Sverige
  • Bone marrow mesenchymal stromal cells (BM-MSCs) have been characterized and used in many clinical studies based on their immunomodulatory and regenerative properties. We have recently reported the benefit of autologous MSC systemic therapy in the treatment of type 1 diabetes mellitus (T1D). Compared with allogeneic cells, use of autologous products reduces the risk of eliciting undesired complications in the recipient, including rejection, immunization, and transmission of viruses and prions; however, comparable potency of autologous cells is required for this treatment approach to remain feasible. To date, no analysis has been reported that phenotypically and functionally characterizes MSCs derived from newly diagnosed and late-stage T1D donors in vitro with respect to their suitability for systemic immunotherapy. In this study, we used gene array in combination with functional in vitro assays to address these questions. MSCs from T1D donors and healthy controls were expanded from BM aspirates. BM mononuclear cell counts and growth kinetics were comparable between the groups, with equivalent colony-forming unit-fibroblast capacity. Gene microarrays demonstrated differential gene expression between healthy and late-stage T1D donors in relation to cytokine secretion, immunomodulatory activity, and wound healing potential. Despite transcriptional differences, T1D MSCs did not demonstrate a significant difference from healthy controls in immunosuppressive activity, migratory capacity, or hemocompatibility. We conclude that despite differential gene expression, expanded MSCs from T1D donors are phenotypically and functionally similar to healthy control MSCs with regard to their immunomodulatory and migratory potential, indicating their suitability for use in autologous systemic therapy.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Alm, Jessica J.Karolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden (author)
  • Heldring, NinaKarolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden (author)
  • Moll, GuidoKarolinska Inst, Ctr Hematol & Regenerat Med, Stockholm, Sweden.;Karolinska Inst, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden.;Karolinska Inst, Dept Lab Med, Div Transfus Med, Stockholm, Sweden.;Karolinska Univ Hosp, Stockholm, Sweden.,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden (author)
  • Gavin, CarolineKarolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden (author)
  • Batsis, IoannisKarolinska Inst, Ctr Hematol & Regenerat Med, Stockholm, Sweden.,Karolinska Institute, Sweden (author)
  • Qian, HongKarolinska Institutet,Karolinska Institute, Sweden (author)
  • Sigvardsson, MikaelLinköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Medicinska fakulteten(Swepub:liu)miksi32 (author)
  • Nilsson, BoUppsala universitet,Klinisk immunologi,Uppsala University, Sweden(Swepub:uu)bonils (author)
  • Kyllonen, Lauri E.Helsinki Univ Hosp, Div Transplantat, Helsinki, Finland.,Helsinki University Hospital, Finland (author)
  • Salmela, Kaija T.Helsinki Univ Hosp, Div Transplantat, Helsinki, Finland.,Helsinki University Hospital, Finland (author)
  • Carlsson, Per-OlaUppsala universitet,Institutionen för medicinsk cellbiologi,Institutionen för medicinska vetenskaper,Uppsala University, Sweden(Swepub:uu)perocarl (author)
  • Korsgren, OlleUppsala universitet,Klinisk immunologi,Uppsala University, Sweden(Swepub:uu)ollekors (author)
  • Le Blanc, KatarinaKarolinska Institutet,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden (author)
  • Karolinska InstitutetKarolinska Institute, Sweden; Karolinska University Hospital, Sweden (creator_code:org_t)

Related titles

  • In:Stem Cells Translational Medicine: Oxford University Press (OUP)5:11, s. 1485-14952157-65642157-6580

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view